Eosinophilic colitis with favorable response to vedolizumab.

Eosinophilic gastroenteritis is a rare, chronic inflammatory disease with eosinophil infiltration in the digestive tract. Treatment typically involves corticosteroids, but new therapies, including vedolizumab, are under evaluation. Vedolizumab inhibits lymphocyte migration to intestinal tissue, impacting eosinophil activity.

Effectiveness and safety of neoadjuvant therapy in triple-negative breast cancer in a real-world population.

Objective: Triple-negative breast cancer is a subtype of aggressive breast cancer. Our aim is to evaluate the effectiveness and safety of neoadjuvant treatment in early-stage triple-negative breast cancer and to identify predictors of pathological complete response.

Methods: This is a single-center, retrospective study involving 79 patients with triple-negative breast cancer who initiated neoadjuvant treatment between January 2017 and October 2022.

"Cap polyposis", refractory to drug treatment, including infliximab.

Cap polyposis is a rare disease characterized by the presence of inflammatory polyps with an adherent fibrin sheath ("cap"), in variable number and size, in the rectum and sigmoid. It presents with tenesmus, mucous stools and rectorrhagia. There is currently no standardized treatment, having been treated empirically with aminosalicylates, oral or rectal steroids, metronidazole, H.

Effectiveness and safety of neoadjuvant therapy in triple-negative breast cancer in a real-world population.

Objective: Triple-negative breast cancer is a subtype of aggressive breast cancer. Our aim is to evaluate the effectiveness and safety of neoadjuvant treatment in early-stage triple-negative breast cancer and to identify predictors of pathological complete response.

Methods: This is a single-center, retrospective study involving 79 patients with triple-negative breast cancer who initiated neoadjuvant treatment between January 2017 and October 2022.